701977-09-5

Usage

Uses

Used in Pharmaceutical Industry:
MK 0364 is used as a therapeutic agent for the treatment of neurological conditions such as epilepsy and neuropathic pain. Its application is based on its ability to modulate the activity of specific potassium channels in the brain and nervous system, which can help reduce abnormal electrical activity and alleviate symptoms associated with these conditions.
Used in Research and Development:
MK 0364 is used as a research compound for further investigation of its potential applications in treating anxiety and depression. Its unique mode of action and complex chemical structure make it a valuable candidate for exploring new therapeutic approaches in the field of neuroscience and drug discovery.
Used in Drug Discovery:
MK 0364 is employed as a lead compound in the development of new drugs targeting potassium channels for the treatment of various neurological conditions. Its potent and selective activity, along with its potential to alleviate symptoms associated with epilepsy, neuropathic pain, anxiety, and depression, make it a promising candidate for further optimization and development into effective therapeutic agents.

InChI:InChI=1/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)

Upstream product

• 605680-62-4 2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanoic acid 
• 622-95-7 4-chlorobenzyl bromide 
• 876365-70-7 N-[(1Z)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylprop-1-en-1-yl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide 
• 1878-67-7 3-Bromophenylacetic acid 
• 1204241-05-3 C₁₅H₁₁BrCl₂O 
• 941280-51-9 2-(3-bromophenyl)-3-(4-chlorophenyl)propionic acid 
• 1002752-54-6 (3S)-3-(3-bromophenyl)-4-(4-chlorophenyl)butan-2-one 
• 941280-52-0 (2R,3S)-3-(3-bromophenyl)-4-(4-chlorophenyl)butan-2-ol 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 
• 913849-17-9 ethyl 2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanoate 
• 610791-48-5 N-[3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]amine hydrochloride 
• 876365-72-9 3-{(1S,2S)-1-(4-chlorobenzyl)-2-[(2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanoyl)amino]propyl}benzamide 
• 732982-66-0 N-(1S,2S)-[2-(3-cyanophenyl)-3-(4-chlorophenyl)-1-methylpropyl]amine 
• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 

Relevant academic research and scientific papers

New efficient asymmetric synthesis of taranabant, a CB1R inverse agonist for the treatment of obesity

Taranabant (1) is a cannabinoid-1 receptor (CB1R) inverse agonist that was recently in late-stage clinical development for the treatment of obesity. The previously employed synthesis exhibited a number of shortcomings for continuing development, and in th

LIQUID PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION OF A SUBSTITUTED AMIDE

A liquid pharmaceutical composition comprising N-[1S,2S]-3-[(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[(5-trifluoromethyl)pyridine-2-yl]oxy}propanamide is disclosed, together with processes of preparing the liquid pharmaceutical compo

Convenient total synthesis of taranabant (MK-0364), a novel cannabinoid-1 receptor inverse agonist as an anti-obesity agent

Being obese has various health problems that are related to type 2 diabetes mellitus, cardiovascular disease, hypertension, hyperlipidemia, and fibrinolytic abnormalities. Merck's taranabant (MK-0364), a CB1R inverse agonist, is currently in Phase 3 clini

Catalytic, enantioselective synthesis of taranabant, a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity

Chiral amide 1 (MK-0364, taranabant) is a potent, selective, and orally bioavailable cannabinoid-1 receptor (CB-1R) inverse agonist indicated for the treatment of obesity. An asymmetric synthesis featuring a dynamic kinetic resolution via hydrogenation fo

Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity

The discovery of novel acyclic amide cannabinoid-1 receptor inverse agonists is described. They are potent, selective, orally bioavailable, and active in rodent models of food intake and body weight reduction. A major focus of the optimization process was to increase in vivo efficacy and to reduce the potential for formation of reactive metabolites. These efforts led to the identification of compound 48 for development as a clinical candidate for the treatment of obesity.

COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY

The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor and a particular cannabinoid CB?1#191 receptor antagonist/inverse agonist, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes associated with obesity, diabetes-related disorders, obesity, and obesity-related disorders.

Cyanation of aromatic halides

A practical, ligand-free cyanation of aryl bromides employs Pd catalyst in combination with a non-toxic cyanide source, Mn[Fe(CN)6] (M=K or Na; n is 3 or 4), or a hydrate thereof, and a base. The reactions are performed in a polar aprotic solvents and provide the corresponding aryl nitrile in 83-96% yield, typically in less than 5 h.

LIQUID AND SEMI-SOLID PHARMACEUTICAL FORMULATIONS FOR ORAL ADMINISTRATION OF A SUBSTITUTED AMIDE

N-[1S,2S]-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-trifluoromethyl]pyridine-2-yl}oxy} propanamide (Compound I) has surprisingly improved solubility and bioavailability in a lipophilic vehicle comprising a pharmaceutically accept

FORMATION OF TETRA-SUBSTITUTED ENAMIDES AND STEREOSELECTIVE REDUCTION THEREOF

The present invention is directed to a practical process for the preparation of an enamide (II) by palladium catalyzed coupling of a primary amide (IV) with a compound of structural formula (III), as shown below: As well as to crystalline forms of a compo

RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS

The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.